Approx. US locations
~9,000
US stores (retail pharmacy locations, the company's own approximation), per CVS Health Q2 2026 results, as of June 30, 2026
Panel refresh
Daily
Signal type
Dwell-confirmed visits
How GSDSI covers CVS
CVS Health operates one of the highest-footprint US pharmacy networks with MinuteClinic embedded healthcare, prescription, and convenience retail under one polygon. GSDSI's mobility panel captures dwell-confirmed store visits for CPG category management in the front-end convenience channel and sell-side competitive research against Walgreens. In-store clinic visits are not modeled; health-care locations fall under our sensitive-location exclusions.
Typical use cases
- Sell-side analysts tracking CVS visitation ahead of quarterly earnings
- Competitive visitation benchmarking vs. Walgreens, Rite Aid
- Trade-area and new-store analysis against competing pharmacy chains
- CPG front-end category management against in-store traffic
Underlying GSDSI products and research
Location & Mobility Data Feed: Foot Traffic, O-D
Daily location and mobility data with a US and Canada feed and country-specific coverage. Origin-destination flows, dwell and visit attribution, consent-based.
Enterprise POI Polygons & Geofencing Data Feed
Global POI inventory and geofence-ready polygons for foot-traffic and site selection. Deduped, polygon-quality validated, refreshed on a per-dataset schedule.
Alternative Data for Finance (Tickerized Signals)
Tickerized consumer signals for fundamental research and quant strategies. Foot-traffic, card, web-intent, and ACR mapped to public equity tickers. Quant-ready.
Competitive Benchmarking Data (Foot Traffic)
Foot traffic, market share, and transaction trends across retail, CPG, and restaurant categories. Track share-of-visit vs. competitors with daily-fresh data.
CPG Signals in Alt Data: 71M DAUs Explained
What transaction-level CPG signals from a 71M DAU panel actually reveal about brand share, category trends, and private-label shift, and how to use them.
Alternative Data in Equity Research: Buyer Guide
A grounded look at where alternative data adds alpha and where it doesn’t, plus a buyer’s checklist for evaluating tickerized signal vendors before signing.